The authors of this study argue that the combination of CXCR4 inhibition with TKI treatment in CML might be a useful approach to override drug resistance and to achieve deeper responses in CML [194]. This evidence concerns the gene CXCR4 and chronic myelogenous leukemia, BCR-ABL1 positive.